ARIAD Pharmaceuticals, Inc. (ARIA) announced long-term durability-of-response data from its Phase 1 trial of Iclusig (ponatinib) in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia, or CML, or Philadelphia chromosome-positive acute lymphoblastic leukemia, or Ph+ ALL.
The study showed that among chronic-phase, or CP, patients, the median durations of major and complete cytogenetic responses, along with major molecular response, have yet to be reached. The median follow-up for CP patients still on study is now more than three years.
These data will highlighted in a presentation at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago.
Michael Mauro, associate professor at the Oregon Health & Science University, Portland, Oregon, said, "These data show that ponatinib continues to provide deep, durable clinical responses in chronic-phase CML patients who failed several prior tyrosine kinase inhibitor therapies. It is noteworthy that these patients are maintaining their responses over this long period of time and that a median duration of response to ponatinib has not yet been reached."
For comments and feedback: editorial@rttnews.com